The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
8
Oral solution containing radiolabelled \[14C\]-Lu AF28996.
Fortrea Clinical Research Unit Ltd
Leeds, United Kingdom
Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces)
Time frame: From baseline (Day -1) up to 23 days post-dose
AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material
Time frame: From date of dosing (Day 1) up to 23 days post-dose
T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material
Time frame: From date of dosing (Day 1) up to 23 days post-dose
AUC0-infinity of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Cmax of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
Tmax of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
T½ of Lu AF28996
Time frame: From date of dosing (Day 1) up to 23 days post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.